抗生素在肿瘤发生发展及免疫治疗中的作用

国际肿瘤学杂志››2021,Vol. 48››Issue (1): 48-51.doi:10.3760/cma.j.cn371439-20200423-00009

抗生素在肿瘤发生发展及免疫治疗中的作用

杨梦雪, 袁满, 童建东, 严雪冰()

扬州大学附属医院肿瘤科 225000

收稿日期:2020-04-23修回日期:2020-08-27出版日期:2021-01-08发布日期:2021-01-21
通讯作者:严雪冰 E-mail:yyxxbb8904@163.com
基金资助:
国家自然科学基金(81902422)

Role of antibiotics in tumor development and immunotherapy

Yang Mengxue, Yuan Man, Tong Jiandong, Yan Xuebing()

Department of Oncology, Affiliated Hospital of Yangzhou University, Yangzhou 225000, China

Received:2020-04-23Revised:2020-08-27Online:2021-01-08Published:2021-01-21
Contact:Yan Xuebing E-mail:yyxxbb8904@163.com
Supported by:
National Natural Science Foundation of China(81902422)

摘要/Abstract

摘要：

近年来,以免疫检查点抑制剂(ICI)为代表性药物的肿瘤免疫治疗成为晚期恶性肿瘤重要的治疗方法。临床前研究发现,肠道微生物群紊乱会降低应用ICI患者的临床获益。最新的数据表明,抗生素可能通过改变肠道微生物群的丰度及组成进一步影响肿瘤的发生发展及免疫治疗疗效。总结抗生素在晚期恶性肿瘤免疫治疗中的作用,可为优化晚期肿瘤患者治疗策略提供新思路。

关键词:抗菌药,免疫疗法,微生物群,预后

Abstract:

In recent years, immunotherapy with immune checkpoint inhibitor (ICI) as the representative drug has become an important treatment method for advanced malignant tumors. Preclinical studies have found that disorders of the gut microbiota can reduce the clinical benefit of patients treated with ICI. The latest data indicate that antibiotics may further affect the occurrence and development of tumors and the efficacy of immunotherapy by changing the abundance and composition of intestinal microbiota. To sum up the role of anti-biotics in the immunotherapy of advanced malignant tumor may provide a new idea for the optimization of treatment strategies for patients with advanced cancer.

Key words:Anti-bacterial agents,Immunotherapy,Microbiota,Prognosis

杨梦雪, 袁满, 童建东, 严雪冰. 抗生素在肿瘤发生发展及免疫治疗中的作用[J]. 国际肿瘤学杂志, 2021, 48(1): 48-51.

Yang Mengxue, Yuan Man, Tong Jiandong, Yan Xuebing. Role of antibiotics in tumor development and immunotherapy[J]. Journal of International Oncology, 2021, 48(1): 48-51.

参考文献26

[1]	Hartmann FJ, Babdor J, Gherardini PF, et al. Comprehensive immune monitoring of clinical trials to advance human immunotherapy[J]. Cell Rep, 2019,28(3): 819-831.e4. DOI: 10.1016/j.celrep.2019.06.049.
[2]	Nie P, Li Z, Wang Y, et al. Gut microbiome interventions in human health and diseases[J]. Med Res Rev, 2019,39(6):2286-2313. DOI: 10.1002/med.21584. doi:10.1002/med.21584pmid:30994937
[3]	Wei MY, Shi S, Liang C, et al. The microbiota and microbiome in pancreatic cancer: more influential than expected[J]. Mol Cancer, 2019,18(1):97. DOI: 10.1186/s12943-019-1008-0. pmid:31109338
[4]	Baba Y, Iwatsuki M, Yoshida N, et al. Review of the gut microbiome and esophageal cancer: pathogenesis and potential clinical implications[J]. Ann Gastroenterol Surg, 2017,1(2):99-104. DOI: 10.1002/ags3.12014. pmid:29863142
[5]	Bullman S, Pedamallu CS, Sicinska E, et al. Analysis of fusobacte-rium persistence and antibiotic response in colorectal cancer[J]. Science, 2017,358(6369):1443-1448. DOI: 10.1126/science.aal5240. pmid:29170280
[6]	Wirbel J, Pyl PT, Kartal E, et al. Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer[J]. Nat Med, 2019,25(4):679-689. DOI: 10.1038/s41591-019-0406-6. doi:10.1038/s41591-019-0406-6pmid:30936547
[7]	Alexander JL, Wilson ID, Teare J, et al. Gut microbiota modulation of chemotherapy efficacy and toxicity[J]. Nat Rev Gastroenterol Hepatol, 2017,14(6):356-365. DOI: 10.1038/nrgastro.2017.20. doi:10.1038/nrgastro.2017.20pmid:28270698
[8]	Wang Y, Wiesnoski DH, Helmink BA, et al. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis[J]. Nat Med, 2018,24(12):1804-1808. DOI: 10.1038/s41591-018-0238-9. doi:10.1038/s41591-018-0238-9pmid:30420754
[9]	Rosa CP, Brancaglion GA, Miyauchi-Tavares TM, et al. Antibiotic-induced dysbiosis effects on the murine gastrointestinal tract and their systemic repercussions[J]. Life Sci, 2018,207:480-491. DOI: 10.1016/j.lfs.2018.06.030. doi:10.1016/j.lfs.2018.06.030pmid:30056862
[10]	Russell B, Garmo H, Beckmann K, et al. A case-control study of lower urinary-tract infections, associated antibiotics and the risk of developing prostate cancer using PCBaSe 3.0[J]. PLoS One, 2018,13(4):e0195690. DOI: 10.1371/journal.pone.0195690. doi:10.1371/journal.pone.0195690pmid:29649268
[11]	Zhang J, Haines C, Watson AJM, et al. Oral antibiotic use and risk of colorectal cancer in the United Kingdom, 1989-2012: a matched case-control study[J]. Gut, 2019,68(11):1971-1978. DOI: 10.1136/gutjnl-2019-318593. doi:10.1136/gutjnl-2019-318593pmid:31427405
[12]	Petrelli F, Ghidini M, Ghidini A, et al. Use of antibiotics and risk of cancer: a systematic review and meta-analysis of observational studies[J]. Cancers (Basel), 2019,11(8):1174. DOI: 10.3390/cancers11081174.
[13]	Sethi V, Kurtom S, Tarique M, et al. Gut microbiota promotes tumor growth in mice by modulating immune response[J]. Gastroenterology, 2018,155(1):33-37.e6. DOI: 10.1053/j.gastro.2018.04.001. pmid:29630898
[14]	Yan C, Tu XX, Wu W, et al. Antibiotics and immunotherapy in gastrointestinal tumors: friend or foe?[J]. World J Clin Cases, 2019,7(11):1253-1261. DOI: 10.12998/wjcc.v7.i11.1253. doi:10.12998/wjcc.v7.i11.1253pmid:31236389
[15]	Schoenfeld AJ, Hellmann MD. Acquired resistance to immune checkpoint inhibitors[J]. Cancer Cell, 2020,37(4):443-455. DOI: 10.1016/j.ccell.2020.03.017. doi:10.1016/j.ccell.2020.03.017pmid:32289269
[16]	Hermel DJ, Sigal D. The emerging role of checkpoint inhibition in microsatellite stable colorectal cancer[J]. J Pers Med, 2019,9(1):5. DOI: 10.3390/jpm9010005.
[17]	Eng C, Kim TW, Bendell J, et al. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial[J]. Lancet Oncol, 2019,20(6):849-861. DOI: 10.1016/S1470-2045(19)30027-0. doi:10.1016/S1470-2045(19)30027-0pmid:31003911
[18]	Aguiar PN Jr, De Mello RA, Hall P, et al. PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data[J]. Immunotherapy, 2017,9(6):499-506. DOI: 10.2217/imt-2016-0150. doi:10.2217/imt-2016-0150pmid:28472902
[19]	Derosa L, Hellmann MD, Spaziano M, et al. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer[J]. Ann Oncol, 2018,29(6):1437-1444. DOI: 10.1093/annonc/mdy103. pmid:29617710
[20]	Pinato DJ, Howlett S, Ottaviani D, et al. Association of prior anti-biotic treatment with survival and response to immune checkpoint inhibitor therapy in patients with cancer[J]. JAMA Oncol, 2019,5(12):1774-1778. DOI: 10.1001/jamaoncol.2019.2785. doi:10.1001/jamaoncol.2019.2785pmid:31513236
[21]	Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors[J]. Science, 2018,359(6371):91-97. DOI: 10.1126/science.aan3706. pmid:29097494
[22]	Kaderbhai C, Richard C, Fumet JD, et al. Antibiotic use does not appear to influence response to nivolumab[J]. Anticancer Res, 2017,37(6):3195-3200. DOI: 10.21873/anticanres.11680. doi:10.21873/anticanres.11680pmid:28551664
[23]	Tinsley N, Zhou C, Tan G, et al. Cumulative antibiotic use significantly decreases efficacy of checkpoint inhibitors in patients with advanced cancer[J]. Oncologist, 2020,25(1):55-63. DOI: 10.1634/theoncologist.2019-0160. doi:10.1634/theoncologist.2019-0160pmid:31292268
[24]	Ahmed J, Kumar A, Parikh K, et al. Use of broad-spectrum anti-biotics impacts outcome in patients treated with immune checkpoint inhibitors[J]. Oncoimmunology, 2018,7(11):e1507670. DOI: 10.1080/2162402X.2018.1507670. doi:10.1080/2162402X.2018.1507670pmid:30377571
[25]	Huang XZ, Gao P, Song YX, et al. Antibiotic use and the efficacy of immune checkpoint inhibitors in cancer patients: a pooled analysis of 2740 cancer patients[J]. Oncoimmunology, 2019,8(12):e1665973. DOI: 10.1080/2162402X.2019.1665973. doi:10.1080/2162402X.2019.1665973pmid:31741763
[26]	Suez J, Zmora N, Zilberman-Schapira G, et al. Post-antibiotic gut mucosal microbiome reconstitution is impaired by probiotics and improved by autologous FMT[J]. Cell, 2018,174(6):1406-1423.e16. DOI: 10.1016/j.cell.2018.08.047. pmid:30193113